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ABSTRACT   
TREATING VERY LARGE NON-SMALL CELL LUNG CANCERS: A SURVIVAL 
ANALYSIS USING NATIONAL CANCER DATABASES. 
Amy C. Moreno, Daniel Morgensztern, Daniel J. Boffa, Roy H. Decker, James B. Yu, 
Frank C. Detterbeck, Zuoheng Wang, Michal G. Rose, and Anthony W. Kim. 
Department of Thoracic Surgery, Yale University School of Medicine, New Haven, CT. 
 
Very large primary non-small cell lung cancers (NSCLC), defined as those >7 cm, 
remain a therapeutic challenge due to known survival disadvantage compared to smaller 
tumors and lack of specific studies in this population. This study compares the effect of 
various treatment modalities on survival of patients with large NSCLC with none or 
positive hilar lymph node involvement (T3>7cmN0 and T3>7cmN1, respectively). 
The Surveillance, Epidemiology, and End Results (SEER) database was used to 
identify patients undergoing a lobectomy or pneumonectomy for T3>7cmN0 NSCLC from 
1999 to 2008. Patients were categorized into groups based on type of surgery performed 
and whether neoadjuvant radiation therapy (NRT) was used. The National Cancer Data 
Base (NCDB) was used to identify adult patients who were diagnosed with T3>7cmN1 
NSCLC from 1999-2005. Nonsurgical treatments included chemoradiation, 
chemotherapy, radiation therapy, or no treatment whereas primary surgical treatments 
included surgery only, chemoradiation or chemotherapy prior to surgery (CxR-S or C-S, 
respectively), chemoradiation or chemotherapy after surgery (S-CxR or S-C, 
respectively), or postoperative radiation therapy (S-PORT). Five-year overall (OS) and 
 
lung cancer specific survival (LCSS) were estimated by the Kaplan-Meier method and 
comparisons made using log-rank tests and Cox regression models. 
A total of 1,301 surgical patients with T3>7cmN0 NSCLC were evaluated using the 
SEER database, including 1,232 undergoing primary surgical therapy (PST) and 69 
receiving NRT. NRT was not associated with improvements in 5-year OS (48% vs. 41%, 
P=.06) or LCSS (59% vs. 52%, P=.12) compared to PST. Lobectomies were associated 
with better 5-year OS (43% vs. 33%; P=.006) and LCSS (54% vs. 43%, P=.005) 
compared to pneumonectomies. On multivariate analysis, NRT did not produce any 
significant advantage in OS (P=.24) and LCSS (P=.21). Using the NCDB, a total of 642 
patients with T3>7cmN1 NSCLC were evaluated: 425 nonsurgical and 217 primary 
surgical treatments. Primary surgical treatments were associated with an improved 5-year 
OS of 28% compared to 8% and 4% for primary nonsurgical treatments and no 
treatments, respectively (P<.001). Specific nonsurgical treatment 5-year OS were 11%, 
5%, 2%, 4% for chemoradiation, chemotherapy, radiation therapy, and no treatment, 
respectively (P<.001). Primary surgical treatment 5-year OS were 16%, 44%, 40%, 40%, 
38%, and 18% for surgery only, CxR-S, C-S, S-CxR, S-C, and S-PORT, respectively 
(P<.001). On multivariate analysis, surgery and chemotherapy in most combinations 
were associated with significantly improved OS compared to chemoradiation only (C-S 
hazard ratio (HR), 0.4 [95% confidence interval, 0.18-0.88], P=.02; CxR-S HR, 0.41 
[0.19-0.9], P=.03; S-C HR, 0.4 [0.19-0.85], P=.02).  
Our results demonstrate that neoadjuvant radiation therapy, which most likely was 
a combination of chemotherapy and radiation, was not associated with improvements in 
OS or LCSS compared to primary surgical therapy for patients with T3>7cmN0 NSCLC. 
 
When feasible, lobectomy appears more beneficial than pneumonectomy in terms of 
long-term survival. For patients with T3>7cmN1 NSCLC, surgery with systemic therapy 
delivered in a neoadjuvant or adjuvant fashion is associated with improvements in long-
term overall survival. Finally, when surgical resection is not feasible, definitive 
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With approximately 288,190 newly diagnosed cases estimated in 2013, lung 
cancer is a dangerously prevalent disease in the United States. It is the second most 
common cancer in both men and women, accounting for roughly 14% of all new cancers. 
As the most common cause of cancer deaths, lung cancer takes the lives of almost one-
third of all cancer patients annually, a toll that surpasses colon, breast, and prostate 
cancer deaths combined
1
. While the chances of a man or woman to develop lung cancer 
in his or her lifetime nowadays is about 1 in 13 or 1 in 16, respectively, it is interesting to 
note that lung cancer was once considered a very rare disease prior to the 20
th
 century. By 
1900, only about 140 cases had been published in medical literature. Shortly thereafter, 
findings of primary lung tumors in autopsied bodies began to rise dramatically. In 1912, 
Isaac Adler, author of the world’s first monograph on lung cancer, was one of the first to 
infer a possible association between tobacco abuse (and alcohol) with the simultaneous 
“decided increase” in incidence of malignant neoplasms of the lung
2
. A global lung 
cancer epidemic was later recognized in the 1940s and 1950s as growing evidence of the 
epidemiology, cellular pathology, and chemical analytics pointed back to cigarettes as the 
primary cause
3
. However, with the expansion of cigarette manufacturing and effective 
propagandizing to the public, this evidence was argued for years while a worldwide 
addictive habit quickly solidified.  
 Tobacco smoking is now undisputedly the leading risk factor for lung cancer. 
According to the 2012 International Agency for Research on Cancer (IARC) risk 
assessment, lung cancer kills about 1.59 million people per year globally with 80-95% of 
cases entirely preventable
4,5
. Other risk factors include radon, a naturally occurring 
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radioactive gas that results from the breakdown of uranium in soil and rocks, asbestos 
exposure, and a history of radiation therapy to the lungs or chest for other cancers such as 
Hodgkin’s lymphoma
5
. Lung cancer is primarily a disease of the elderly with two out of 
three people diagnosed being over the age of 65. This finding has been thought to 
correlate with an increased likelihood of tobacco smoke exposure with increasing age. 
For unknown reasons, black men are about 20% more likely to develop lung cancer than 
white men
1
. Major public awareness campaigns, banning of cigarette smoking in public 
areas, and a steadfast mission to detect and aggressively treat lung cancer as early as 
possible have all created a small appearing yet significant impact towards thwarting the 
rising trend of lung cancer. Over the past decade, rates for new lung and bronchus 
cancers have been falling on average 1.3% each year and mortality trends are similarly 
decreasing by about 2.3% per year for men and 0.7% per year among women
6,7
. 
 When analyzing lung cancers histologically, they can be broadly divided into two 
main types: small cell and non-small cell lung cancer (NSCLC). NSCLC constitutes the 
majority of lung cancers and includes histologic subtypes such as adenocarcinoma, large 
cell carcinoma, and squamous cell carcinoma. Roughly one-quarter of patients with 
NSCLC are diagnosed at an early stage (stage I or II), and treatment typically includes 
surgery with or without chemotherapy in order to achieve curative rates of 60-80% and 
40-50% for stages I and II disease, respectively
8-10
. On the other extreme of the spectrum, 
treatment goals for stage IV disease usually involve palliative measures to deal with 
metastatic disease. For the remaining 35% to 45% of patients diagnosed with stage III 
NSCLC, curative-intent treatment is a controversial topic. The differences in treatment 
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within stage III owes to the inclusion of a heterogeneous group of lesions that constitute 
this stage.  
According to the 7
th
 edition of the American Joint Committee on Cancer (AJCC) 
and the International Union Against Cancer (UICC) staging system, stage III lung cancer 
can be divided into two broad subcategories, stage IIIA and stage IIIB disease
11
. Each 
stage can be further analyzed by the TNM classification method that incorporates 
information regarding tumor dimensions (T), lymph node invasion (N), and whether 
metastatic disease is present (M). Stage IIIA mirrors the heterogeneity of all of stage III 
disease as it is also constituted by a heterogeneous mix of lesion sets [Table 1]. With 
respect to tumor size and/or extension, T3 lesions encompass lesions that invade the chest 
wall, are central in nature, or are associated with additional tumors in the same lobe. 
Tumors that are greater than 7 cm also fall into the T3 primary tumor category.  
Tumor size has long since been recognized as a valuable prognostic factor in 
NSCLC. Adopted worldwide in 1974, the TNM classification is revised nearly every 10 
years. Prior to the 7
th
 edition of the AJCC staging system, the 6
th
 edition defined only one 
tumor size cut off of 3 cm to separate T1 from T2 lesions. This threshold value for tumor 
size was selected after several studies demonstrated a significant difference in survival 
between patients with ≤3 cm (T1) and >3 cm (T2) lesions
12-15
. Since then more studies 
indicating survival differences at other larger tumor sizes led to the further division of T2 
lesions to T2a (>3 cm but ≤5 cm) and T2b (> 5 cm but ≤7 cm) lesions and the upstaging 
of tumors >7 cm to a T3 status
11,16,17
. These major revisions that focused mainly on the T 
descriptor carry a significant impact on diagnostic staging and subsequent treatment 
selection. More specifically, very large tumors >7 cm with no lymph node involvement 
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were upstaged from stage IB to stage IIB (T3>7 cmN0) disease while tumors >7 cm with 
positive ipsilateral hilar lymph node involvement were upstaged from stage IIB to stage 
IIIA (T3>7 cmN1) disease. 
Many clinicians, in particular surgeons, would agree that T3N0 tumors benefit 
from surgical resection as the initial mode of therapy. Current National Comprehensive 
Cancer Network (NCCN) and American College of Chest Physicians (ACCP) guidelines 
recommend lung-sparing anatomic resections (lobectomy) over pneumonectomies if 
anatomically appropriate and margin-negative resections can be achieved
10,18
. The use of 
definitive, neoadjuvant, or adjuvant chemotherapy with or without radiation therapy for 
this subset of patients with early stage disease is arguable due to the absence of metastatic 
spread to local lymph nodes and   reasonably high curative rates with surgery alone. 
However, data from the CALGB study which demonstrated that a statistically significant 
survival advantage exists for patients with early stage NSCLC tumors ≥4 cm who are 
treated with adjuvant paclitaxel/carboplatin would then suggest that given the large 
nature of these tumors, there is a benefit of adding adjuvant therapy
19
. Moreover, there 
may be a potential impact of neoadjuvant therapy on “downstaging” or reducing tumor 
burden prior to surgical resection for patients with very large tumors that are categorized 
as early stage disease. In clinical practice, the optimal strategy for this group remains 
undefined.  
Similarly, the optimal treatment strategy for T3>7 cmN1 NSCLC is controversial. 
Part of the confusion results from a lack of studies analyzing patterns of care and 
associated survival outcomes for this particular group of patients. As noted earlier, Stage 
IIIA disease represents a heterogeneous set of locally advanced lung cancers that 
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occasionally include surgical resection as part of a multimodality treatment 
algorithm
9,18,20
. Most studies analyzing the role of neoadjuvant or adjuvant therapy for 
the very large T3 lesion subset of T3 lesions are frequently buried among general data 
analyzing neoadjuvant or adjuvant therapy for stage II or III disease
21-23
. With the recent 
upstaging of T3>7 cmN1 NSCLC to a Stage IIIA designation it is difficult to assess the 
effects of treatment on survival for this subset of patients when most studies on Stage 
IIIA disease are primarily focused on treating mediastinal or N2 nodal disease. Looking 
at this heavily studied population, patients with N2 nodal disease who comprise the 
majority of Stage IIIA NSCLC cases are approached with a wide variation in treatment 
strategies that are heavily influenced by physician interpretation of the actual extent of 
the disease and the patient’s ability to withstand treatment
24-26
. Overall, there is a general 
consensus that patients with Stage III NSCLC would benefit from a multimodality 
therapeutic approach whenever feasible
20,27
. However, it is arguable that results from 
studies evaluating the effect of various treatments for N2 nodal disease can be directly 
applied to patients with T3>7 cmN1 NSCLC lesions.  
In general, there are not very many studies that specifically address variations in 
the treatment of T3>7 cmN0 and T3>7 cmN1 lesions. It is clear that very large tumors that 
are greater than 7 cm with no or minimal hilar lymph node involvement present a unique 
set of problems for clinicians. Large lesions typically will not respond completely to the 
effects of definitive chemotherapy and radiation therapy. Similarly, as aforementioned, 
the benefit of these very large tumors in the context of neoadjuvant therapy remains 
questionable. The challenge associated with resecting these large tumors is that the extent 
of the operation required to remove these lesions is substantial and often times followed 
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by adjuvant therapy in clinical practice. To our knowledge, there has been no study 
assessing current treatment patterns and their effect on long-term survival for patients 




STATEMENT OF PURPOSE AND SPECIFIC HYPOTHESIS 
 
The purpose of this study was to examine the efficacy of different treatment strategies on 
long-term survival of patients with very large NSCLC tumors clinically staged as 
T3>7cmN0 or T3>7 cmN1 using large national datasets. Our primary hypothesis is that there 
is a practice pattern that exists which may be associated with an improved outcome for 
very large tumors with none or minimal lymph node burden. Our secondary hypothesis is 
that within this group, whether there is a difference or not, there are specific 




1. To identify current patterns of treatment for very large NSCLCs that are clinically 
staged as T3>7cmN0 or T3>7cmN1 
2. To determine the practice pattern associated with the best clinical outcomes 
including the longest survival 
3. To identify factors that are associated with improved clinical outcomes compared 
to other patients with stage T3>7cmN0 or T3>7cmN1 NSCLC undergoing alternative 





NOTE: All data analysis described below was performed by the primary author. 
Data Sources 
 This study utilized two national cancer databases. The Surveillance, 
Epidemiology, and End Results database provided clinical, demographic, and treatment 
data for patients diagnosed with very large (>7 cm) NSCLC tumors with no lymph node 
involvement (T3>7cmN0 disease). The National Cancer Database provided clinical, 
demographic, treatment and overall survival data for patients diagnosed with very large 
(>7 cm) NSCLC tumors with positive ipsilateral hilar lymph node involvement 
(T3>7cmN1 disease). 
 
The Surveillance Epidemiology End Results (SEER) Public-Use Dataset 
The Surveillance, Epidemiology, and End Results (SEER) database, a national 
cancer surveillance program, has collected clinicopathologic data on all incident cancer 
cases since 1973 and now includes 18 regional population-based cancer registries that 
cover approximately 28% of the United States population. Sponsored by the National 
Cancer Institute, the database is highly representative of national demographics and 
contains information on primary tumor site, tumor histology and morphology, stage at 





We restricted the analysis to patients who were of age 20 years and older and 
were diagnosed with NSCLC from 1999 to 2008. As the current seventh edition AJCC 
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lung cancer staging definition for Stage IIB tumors is broad and complex, we selectively 
specified for a clinical TNM staging diagnosis of a tumor size >7 cm with no clinical 
lymph node involvement (cN0) or metastasis (cM0) in our inclusion criteria. All eligible 
patients had histologically confirmed NSCLC. The histology of the tumors coded in the 
SEER database according to the third edition of the International Classification of 
Disease for Oncology (ICD-O-3) was used to classify tumors into the following five 
categories: large cell carcinomas (ICD-O-3 codes 8012 and 8013); squamous cell 
carcinomas (ICD-O-3 codes 8050-8052 and 8070-8078); adenocarcinomas (ICD-O-3 
codes 8140, 8141, 8143, 8147, 8250-8255, 8260, 8310, 8430, 8480, 8481, 8490, and 
8571-8575); adenosquamous carcinomas (ICD-O-3 codes 8560 and 8570); and other 
NSCLC tumors (ICD-O-3 codes 8010, 8020, 8046)
29
. All patients with distant metastasis 
or tumor sizes less than 7 cm were excluded. The SEER program Coding and Staging 
Manual was consulted to select patients who received definitive surgical therapy in the 
form of a lobectomy (surgical codes 30-45) or pneumonectomy (surgical codes 55-70)
30
. 
These patients were then categorized into groups depending on type of surgery performed 
and whether neoadjuvant radiation therapy (NRT) was provided prior to surgery. The 
final sample size included 1,301 patients.  
 
The National Cancer Database (NCDB) 
The National Cancer Data Base (NCDB) is a joint project of the Commission on 
Cancer of the American College of Surgeons and the American Cancer Society. Begun in 
1989, it is a nationwide oncology outcomes database that captures detailed information of 
nearly 70% of all newly diagnosed cases of cancer in the United States and currently 
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contains over 29 million records from hospital cancer registries across the country
31
. 
Therefore, the NCDB is an excellent resource to investigate patient and tumor 
characteristics, radiation, chemotherapy, complications, and long-term survival. The data 
used in this study are derived from a deidentified NCDB file. The American College of 
Surgeons and the Commission on Cancer have not verified and are neither responsible for 
the analytic or statistical methodology employed, nor the conclusions drawn from these 
data by the investigator. All information regarding patient and tumor characteristics, 
initial treatment, and outcomes were selected for the cohort using the “βPUF (Participant 






The analysis was restricted to patients who were age 20 years and older and 
diagnosed with NSCLC as their only cancer diagnosis from 1999 to 2005. The 
International Classification of Disease for Oncology (ICD-O-3) codes used in the NCDB 
to identify the NSCLC cohort has been previously described above in the “The 
Surveillance Epidemiology End Results (SEER) Public-Use Dataset” section and the 
following subcohorts were created: large cell carcinomas, squamous cell carcinomas, 
adenocarcinomas, adenosquamous carcinomas, and other NSCLC tumors. All patients 
had a documented tumor size >7 cm but ≤20 cm, clinically positive ipsilateral lymph 
node involvement (cN1) and no distant metastasis (cM0). There is a group of patients in 
the NCDB with tumor sizes labeled as 7 cm which could potentially include a subset of 
patients with larger tumors that were estimated downward, but for the purposes of this 
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portion of the study which focused on proper T3>7cmN1 NSCLC identification they were 
excluded. Patients who received surgical therapy in the form of lobectomy or 
pneumonectomy with negative surgical margins were included. Similar surgical codes as 
recorded in the SEER T3>7cmN0 NSCLC analysis above were used.  
Treatment combination sequences were determined for each patient using NCDB 
data items that described the date of treatment (either surgical, chemotherapy/systemic, or 
radiation therapy) in relation to date of diagnosis. The possible treatment modalities for 
the nonsurgical sub-cohort (NST) included no treatment (None); chemotherapy only (C); 
radiation therapy only (RT); or chemoradiation therapy (CxR). The primary surgical 
treatment (PST) combinations included the following: surgery only (S); chemotherapy 
prior to surgery (C-S); chemoradiation prior to surgery (CxR-S); surgery followed by 
chemotherapy (S-C); surgery followed by chemoradiation (S-CxR); or surgery and 
postoperative radiation therapy (S-PORT).  
Preoperative or neoadjuvant radiation therapy is often a proxy for preoperative 
chemoradiation and is seldom provided without chemotherapy prior to surgery. However, 
we found minimal patients with records indicating neoadjuvant radiation therapy without 
chemotherapy prior to surgery. As this treatment modality represented a disproportionate 
minority, it was excluded from the analysis. Any patient with distant metastasis or 
records indicating therapy was for palliative measures was excluded. Patients undergoing 
surgical resections with positive margins were also excluded for several reasons 
including small sample size (less than 10% of the surgical population) and the likelihood 
that this select group of patients received adjuvant therapy due to the positive surgical 
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margins which could therefore skew the results in evaluating the impact of adjuvant 
therapy after complete surgical resection. The final sample size included 642 patients. 
 
Variables 
Patient information obtained from the SEER database included gender, age, 
race/ethnicity, age at diagnosis, histology and size of primary tumor, stage along with 
degree lymph node involvement, type of surgery, the performance of neoadjuvant 
radiation therapy (NRT), survival time, and cause of death. Patient information obtained 
from the NCDB included gender, age, race/ethnicity, age at diagnosis, histology and size 
of primary tumor, stage along with degree lymph node involvement, type of surgery, the 
addition or absence of neoadjuvant and adjuvant therapy, and survival time in months.  
For both databases, patients who had a lobectomy include a simple lobectomy, 
sleeve lobectomy, bilobectomy, and extended lobectomy while those with a 
pneumonectomy consist of both a simple and extended pneumonectomy. The location of 
each tumor was identified for each patient and categorized into one of the following 
groups: right upper lobe (RUL), right middle lobe (RML), right lower lobe (RLL), left 
upper lobe (LUL), or left lower lobe (LLL) lesions.  
Overall survival (OS) was the primary study endpoint and was defined as the time 
from diagnosis to the date of death from any cause. Lung cancer-specific survival 
(LCSS), defined as the time of diagnosis to the date of death from lung cancer, was also 
evaluated in our SEER database analysis. The NCDB, however, lacks data regarding lung 
cancer specific death and therefore LCSS was not evaluated for this portion of the study. 
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Pertaining to the NCDB only, four types of treatment facilities comprised of 
community cancer programs (CCP), comprehensive community cancer programs 
(Comprehensive CCP), teaching/research centers, or others were also included in all 
analysis. Both CCP and Comprehensive CCPs have full range of services for cancer care; 
however CCPs treat at least 300 cancer patients a year whereas Comprehensive CCPs 
treat at least 650 cancer patients annually. Variables that were considered but could not 
be included in the study due to limitations of available data in the NCDB included 
performance status, specific details regarding staging procedures (i.e. CT/PET imaging, 
lymph node staging procedure), medications, and comorbidities (a comorbid condition 
scale in the form of Charlson/Deyo scores is available in the NCDB but only from 2003 
onward and thus was not included in our multivariate analysis).    
 
Statistical Analysis 
T3>7cmN0 NSCLC, SEER Analysis 
The overall survival (OS) and lung cancer-specific survival (LCSS) functions 
stratified by type of surgery in the presence or absence of NRT were calculated using the 
Kaplan-Meier method. Patients who were still alive at the end of the study were treated as 
censored observations in the survival analysis. The log-rank test was used to evaluate 
whether there were differences in the OS and LCSS among the treatment groups. 
Comparisons on patient and tumor characteristics and provided therapy amongst different 
age groups were performed using the Chi-squared test. The multivariable Cox regression 
model was used to assess the effect of NRT followed by surgery as an independent 
predictor of OS and LCSS. Hazard ratios (HR) and corresponding 95% confidence 
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intervals were constructed in models adjusted for patient and tumor characteristics. Data 
analysis was performed using SAS for Windows, version 9.2 (SAS Institute; Cary, NC). 
 
T3>7cmN1 NSCLC, NCDB Analysis 
Comparisons on patient and tumor characteristics and provided therapy amongst 
different age groups were performed using the Chi-squared test. The OS functions 
stratified by type of surgery in the presence or absence of neoadjuvant and adjuvant 
therapy were calculated using the Kaplan-Meier method. Patients who were still alive at 
the end of the study were treated as censored observations in the survival analysis. The 
log-rank test was used to evaluate whether there were differences in the OS among the 
treatment groups. The multivariable Cox regression model with backward elimination of 
covariates with a P value >0.1 was used to assess whether various patient and tumor 
characteristics (age, sex, race, histology, location of tumor, tumor size, facility type) 
along with chosen therapy were significant independent predictors of OS. Hazard ratios 
(HR) and corresponding 95% confidence intervals were constructed in models adjusted 
for patient and tumor characteristics and therapeutic approaches. Data analysis was 
performed using SAS for Windows, version 9.2 (SAS Institute; Cary, NC). Statistical 





T3>7 cmN0 NSCLC, SEER Analysis  
Patient and tumor characteristics 
 The cohort was composed of 1,301 patients of whom 69 patients (5%) received 
NRT followed by surgery as compared to 1,232 patients (95%) who had primary surgical 
therapy (PST) (Table 1). The median follow-up time for the entire cohort was 25 months 
(mean, 35 months; range, 0-131 months).  The median age of the total population was 68 
years (mean, 67 years; range, 31- 94 years). Forty-nine patients (71%) in the NRT group 
were male and 800 patients (65%) who had PST were male. No male over 80 years of age 
received NRT in comparison to 92 males (7%) above the age of 80 who received PST. 
Most patients were Caucasian in both treatment groups (88% NRT; 86% PST). By the 
end of the study period, 60% of the cohort (779 patients) had expired due to either lung 
cancer-related mortality (568 patients; 44%) or other causes of death. 
Adenocarcinoma was the predominant histology comprising 46% of the entire 
cohort (593 patients) followed by squamous cell carcinoma which comprised 38% (500 
patients) of the entire cohort. In the NRT group, squamous cell carcinoma (42%; 29 
patients) was more prevalent than adenocarcinoma (29%; 20 patients). Tumor size did 
not significantly vary among the different age populations (P=.16) in the entire cohort 
and between the two treatment groups. Overall, patients with tumor sizes 8-8.9 cm had 
the highest incidence of definitive treatment with either NRT followed by surgery (21 
patients, 30%) or PST (391 patients, 32%) as compared to those with larger tumors. 
Tumors 7.1-7.9 cm were the second most prevalent size group in the overall cohort (288 
patients; 22%). Although distribution of tumor size was nearly equal among the different 
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age and treatment groups, tumor lobe location varied significantly (P<.0001). For the 
entire cohort, right-sided tumors were more common than left-sided (56% vs. 44%) with 
RUL and RLL lesions accounting for 52% of all tumors. Nearly 85% of patients treated 
with NRT had upper lobe lesions (RUL, 46%; LUL, 38%). 
 
Therapeutic approach 
For the entire cohort, lobectomy was the most commonly employed surgical 
approach with 85% of the population (1,110 patients) having undergone this type of 
resection. The remaining 15% (191 patients) underwent pneumonectomy. The incidence 
of lobectomies performed increased with advancing age while pneumonectomy incidence 
decreased with increased age (P=<.0001). As noted earlier, PST was performed on the 
majority of patients whereas only 5% (69 patients) received NRT followed by surgery. 
Paralleling the overall cohort, patients in the NRT group underwent lobectomy (53 
patients, 77%) more than pneumonectomy. Upon analysis of therapy provided in relation 
to age, the incidence of NRT decreased with advanced age while the incidence of PST 
increased to a peak of 35% for patients between the ages of 70-79 years (P<.0001). The 
majority of patients treated with NRT were among the youngest age groups (20-69 years, 
83%) whereas PST was performed mainly on a higher age population (60-79 years; 66%) 
(Table 1).  
The occurrence of NRT and PST was also analyzed in relation to tumor size. 
Patients with smaller tumor sizes in the overall cohort had a higher incidence of being 
treated with either NRT followed by surgery or PST than patients with increased tumor 
size. Similarly, smaller tumors were more likely to have been treated with a lobectomy or 
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pneumonectomy as compared to larger tumors, although the proportion of lobectomies 
over pneumonectomies was greatest for tumors between 8-8.9 cm (Fig. 1).    
 
Univariate survival analysis 
The addition of NRT was not associated with improvements in the 5-year OS 
(48% vs. 41%, P= .06) or LCSS (59% vs. 52%, P=0.12) compared to PST (Fig. 2). By 
type of surgery performed, lobectomies were associated with significantly improved 5-
year OS (43% vs. 33%; P=.006) and LCSS (54% vs. 43%, P=.005) in comparison to 
pneumonectomies for the entire cohort (Fig. 3). When patients were further divided by 
type of surgery performed in the presence or absence of NRT, NRT did not significantly 
improve the 5-year OS (NRT, 51% vs. PST, 43%; P=.08) or LCSS (NRT, 60% vs. PST, 
54%; p=.19) in patients who had a lobectomy. Similarly, patients who had a 
pneumonectomy did not benefit by the addition of NRT prior to surgery when 
considering 5-year OS (NRT, 36% vs. PST, 32%; P=.33) and LCSS (NRT, 56% vs. PST, 
42%; P=.24). Irrespective of survival time, however, the survival curves for PST, in 
general, were consistently worse than for NRT followed by either a lobectomy or 
pneumonectomy.   
 
Multivariate analysis 
After adjusting for patient and tumor characteristics, NRT was not associated with 
significantly improved OS (P=.24) and LCSS (P=.21) for the entire cohort. Multivariate 
regression analysis identified gender, age, tumor size, and type of surgery performed as 
significant factors affecting OS, whereas only age, tumor size, and type of surgery were 
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found to significantly impact LCSS. Tumors ≥10 cm were associated with worse OS 
(hazard ratio [HR] 1.39; P=.007) and LCSS (HR 1.54; P=.002) when compared to tumors 
7.1-7.9 cm. Pneumonectomies were associated with significantly worse OS (HR, 1.32; 
P=.007) and LCSS (HR, 1.38; P=.005) when compared to lobectomies (Table 2).  
In a secondary analysis on the 69 patients who underwent NRT prior to surgery, 
gender statistically affected survival with females having better OS (HR 0.27 [95% 
confidence interval, 0.1-0.7], P=.007) and LCSS (HR 0.13 [0.03-0.51], P=.003) as 
compared to males. Adenosquamous tumors had a significantly increased overall (HR 
6.18 [1.26-30.2], P=.02) and lung-cancer specific (HR 11.69 [2.13-64.19], P=.005) 
mortality risk than other histological types. The use of NRT prior to a lobectomy did not 
produce a significant advantage in OS (P=.86) or LCSS (P=.7) in comparison to NRT 
followed by a pneumonectomy (Table 3). 
 
T3>7 cmN1 NSCLC, NCDB Analysis 
Patient and tumor characteristics 
The overall cohort was composed of 642 patients of whom 425 patients (66%) 
underwent nonsurgical therapy (NST) and 217 patients (34%) underwent primary 
surgical therapy (PST).  The median age of the entire cohort was 68 years (range, 29-90 
years) with a median follow up time of 11 months (range, 0-143 months). The majority of 
patients were male (390 patients, 61%) and Caucasian (539 patients, 84%) and between 
the ages 60-79 years (415 patients, 65%). By the end of the study period, 88% of the 




Therapeutic approach  
 Among the 425 NST patients, 43% (184 patients) were treated with CxR, 16% 
RT, 15% Chemo, and 26% None. For the PST patients, 49% had S, 11% C-S, 14% CxR-
S, 16% S-C, 5% S-CxR, and 5% S-PORT. Lobectomy was the most commonly employed 
surgical approach with 60% (131 patients) of the PST population having undergone this 
type of resection (P=.002). The remaining 40% of the PST group underwent 
pneumonectomy. For the entire cohort, definitive CxR was the most prevalent treatment 
among all age groups except patients ≥80 years of age where 36% (28 patients) received 
no treatment followed by 23% (18 patients) RT only. About half of the patients in the 
overall cohort were treated in a comprehensive cancer center program (51%, 330 
patients). A similar proportion was noted in the NST and PST groups separately. 
 
Pathologic lymph node involvement 
For PST patients, pathologic lymph node involvement (pN) was evaluated. 
Among 56 patients who underwent neoadjuvant therapy prior to surgical resection (C-S, 
CxR-S), 45% had an indeterminate pN reported (pNX), 27% had pN0, 25% had pN1 and 
3% had pN2. Patients who underwent surgical resection in the absence or presence of 
adjuvant therapy (S, S-C, S-CxR, S-PORT; n= 161) had 14% pN0, 72% pN1, 8% pN2, 
and 6% pNX (P<.001).  
 
Univariate survival analysis 
 Surgery was associated with significant improvements in 5-year OS (PST, 28%) 
compared to 8% and 4% 5-year OS for NST and None, respectively (P<.001) (Fig. 4). 
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Lobectomy was associated with a significantly better 5-year OS compared to 
pneumonectomy among PST patients (L, 31%; P, 23%; P=.03). Smaller tumor sizes were 
associated with improved OS compared to tumors ≥10 cm for the PST cohort (P= .006) 
whereas tumor size variation did not affect OS for NST patients (P=.2).  
 The long-term survival of surgical and nonsurgical patients was further analyzed 
by dividing patients by specific type of therapy provided. For NST patients there was a 
significant stepwise improvement in 5-year OS with the addition of systemic therapy over 
localized radiation therapy (None, 4%; RT, 2%; Chemo, 5%; CxR, 11%; P<.001). 
Surgical patients who only received localized therapy had worse 5-year OS in 
comparison to any multimodality treatment combination which included chemotherapy 
(S, 16%; S-PORT, 18%; C-S, 40%; CxR-S, 44%; S-C, 38%; S-CxR, 40%; P<.001) (Fig. 
5).       
 
Multivariate analysis 
 After adjusting for patient and tumor characteristics, multivariate regression 
analysis on the entire cohort identified age and type of surgery performed as significant 
factors affecting OS (Table 5). Pneumonectomy was associated with a 49% increased 
likelihood of death compared to lobectomy (hazard ratio [HR] 1.49 [95% confidence 
interval, 1.08-2.05], P=.01). Type of therapy was also found to be an independent 
predictor of OS. Using definitive CxR as a reference, chemotherapy had a nonsignificant 
increase in HR whereas all other nonsurgical therapeutic approaches had a significantly 
increased likelihood of death: Chemo HR 1.25 [0.93-1.68], P=.13; RT HR 1.5 [1.12-
2.01], P=.007; None HR 2.87 [2.23-3.69]; P<.001. Local therapy in the form of surgery 
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only was not associated with a significant difference in survival compared to definitive 
CxR (S HR 0.8 [0.41-1.54], P=.5) whereas nearly all surgery with chemotherapy 
combinations were associated with statistically improved OS in comparison to CxR only 
(C-S HR 0.4 [0.18-0.88], P=.02; CxR-S HR 0.41 [0.19-0.9], P=.03; S-C HR 0.4 [0.19-
0.85], P=.02) with the exception of S-CxR which demonstrated a trend towards survival 
improvement (HR 0.5 [0.19-1.34], P=.17).  
 A separate multivariate analysis on the NST groups paralleled the results of the 
overall cohort. Monotherapy was associated with an increased likelihood of death 
compared to chemoradiation (Chemo HR 1.2 [0.92-1.66], P=.16; RT HR 1.5 [1.14-2.05], 
P=.005). A comparison between the nonsurgical therapies demonstrated no significant 
differences in HR between chemotherapy and RT but all three forms of NST were 
associated with significantly improved survival compared to no treatment. In a separate 
analysis of PST patients, tumors ≥10 cm were associated with worse OS (HR 1.89 [1.2-
3]; P=.007) when compared to tumors 7.1-7.9 cm (Table 6). As seen on analysis of the 
overall cohort, all multimodality therapies incorporating chemotherapy in a neoadjuvant 
or adjuvant fashion among PST patients were associated with significantly reduced 
likelihood of death compared to surgical resection only with the exception of S-CxR 
which had a nonsignificant reduction in HR of 0.6 [0.26-1.35], P=.22. Finally, 
pneumonectomies were associated with a significantly worse OS (HR 1.43 [1.02-1.99]; 




T3>7 cmN0 NSCLC, SEER Study 
Surgery in the form of a lobectomy or pneumonectomy depending on the extent of 
disease is still considered the gold standard, primary treatment for stage II NSCLC 
disease. Adjuvant chemotherapy is sometimes recommended in certain high-risk cases in 
order to reduce the risk of distance metastases which is the primary cause of death in 
patients with NSCLC who die within 5 years of a complete surgical resection
8,33
 
However, the use of neoadjuvant therapy remains controversial for the management of 
early stage NSCLC. This study is reflective of current practice patterns for this subset of 
patients with Stage IIB NSCLC in that 95% of the cohort underwent surgery in the 
absence of neoadjuvant therapy.  
For early stage disease, complete surgical resection offers reasonably high rates of 
cure. Definitive radiation therapy is only recommended for patients with early stage lung 
cancer who are medically inoperable or refuse surgery due to potential adverse effects 
from treatment-related toxicities and limited survival benefit
33
. In the SEER database, 
neoadjuvant radiation therapy (NRT) was assumed to be a proxy for preoperative 
chemoradiation due to the fact that preoperative radiation therapy alone has been 
eschewed as the standard of care practice for at least two decades. Presumably, all 
patients in this study had surgery of the primary tumor as part of a curative intent 
paradigm. As stage II lung cancer has lower survival rates than stage I disease after 
surgical resection, in part, due to higher distant recurrences the administration of 
preoperative chemotherapy in addition to NRT would seem reasonable in order to 
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minimize systemic dissemination. This same rationale has been the justification for 
trimodality therapy among patients with more advanced stages of resectable lung cancer.  
This study did not demonstrate a significant survival benefit associated with NRT 
prior to surgery in patients with T3>7 cmN0 NSCLC tumors. The absence of a survival 
difference mirrors the mixed survival results associated with neoadjuvant chemoradiation 
followed by surgical resection for locally advanced NSCLC
21,34-37
.  However, the 5-year 
OS and LCSS rates achieved with NRT were non-significantly improved after trimodality 
treatment in comparison to PST. Possible reasons for the absence of survival benefit in 
our analysis might be inadequate power in the NRT group, the potential use of NRT on 
larger tumors that underwent shrinkage prior to surgical resection, and variations in 
radiation administered lending to the need to further investigate this finding on a larger 
scale. 
The role of neoadjuvant or induction therapy has long since been studied in patients 
with resectable, early stage NSCLC. Neoadjuvant chemotherapy was shown to be 
feasible and safe by the Bimodality Lung Oncology Team (BLOT) trial in 2003
38
 and to 
produce significantly lower risks in distant cancer recurrence in early stage NSCLC
23
. In 
two consecutive Intergroupe Francophone de Cancerologie Theracique or IFCT phase-III 
trials, patients with stage IB or II NSCLC were given platinum-based neoadjuvant 
chemotherapy followed by surgery and pathologic complete response (pCR), defined by 
the absence of viable cancer cells in the resected surgical specimen, was evaluated. 
Among the 492 patients analyzed, 41 (8.3%) achieved pCR and upon multivariate 
analysis, pCR after preoperative chemotherapy was found to be a strong and favorable 
prognostic factor of OS (Relative Risk [RR]= 0.34; 95% CI = 0.18–0.64) and disease-free 
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survival (RR = 0.29; 95% CI = 0.16–0.56). Patients with Stage IB/II NSCLC in this study 
who achieved pCR had a significantly improved 5-year OS of 80% compared with 55.5% 
in the non-pCR group
39
.  
Some clinicians have advocated the addition of preoperative radiation therapy to 
systemic therapy in order to improve control of localized disease to lead to more of a 
complete response than neoadjuvant chemotherapy alone. In a smaller study by Lococo et 
al., 31 patients with T3/T4 node-negative NSCLC were given induction 
chemoradiotherapy prior to surgery and survival patterns evaluated and compared to 40 
T3/4N0 patients who directly underwent surgery. Reasonably safe and low toxicity rates 
were recorded and complete pathologic response was obtained in 22% of the neoadjuvant 
therapy group. Pathologic downstaging after neoadjuvant therapy, whether complete or 
partial, was found to be the only independent factor associated with a better outcome 
after surgery. Surprisingly, no significant differences were found when 5-year OS in the 
neoadjuvant group (44%) and the surgery only group (37%) were compared
40
. These 
results are similar to this study in that patients who received neoadjuvant therapy 
exhibited a trend towards improved, though non-significant, survival rates compared to 
patients who underwent surgical resection only (48% vs. 41%, respectively).  
As with any form of surgical treatment, complete surgical resection is essential in 
offering the best chance for cure. In Lococo et al.’s study, patients who underwent an 
incomplete resection of their tumor had a rate of dying that was greater than 5 times when 
compared to patients with negative surgical margins
40
. Our study evaluated long-term 
survival of patients treated with surgery who obtained negative margins in order to 
exclude patients that were likely to receive adjuvant therapy for treatment of residual 
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disease. Given the very large nature of T3>7 cmN0 NSCLC tumors, complete surgical 
resection becomes increasingly challenging so the use of neoadjuvant therapy in order to 
potentially reduce tumor burden or to allow for a more conservative surgery such as a 
lobectomy is appealing. However, our results demonstrated no significant difference in 
long-term survival compared to surgery alone. 
Apart from achieving complete surgical resection, the type of surgery performed 
may heavily affect survival patterns. No reports regarding randomized trials comparing 
lobectomies to pneumonectomies for patients with NSCLC can be found in the literature 
although several retrospective studies have shown improved 5-year OS rates of about 37-
48% with a lobectomy compared to 29-36% with a pneumonectomy
41,42
. With current 
ACCP guidelines recommending a lobectomy over a pneumonectomy whenever 
complete pathologic resection can be obtained
8,33
, our study demonstrates that this 
recommendation is commonly applied in clinical practice as 85% of the entire cohort had 
undergone this type of surgical resection. Moreover, lobectomies in our study were 
associated with a similar and significantly improved 5-year OS estimate of 43% 
compared to 33% with pneumonectomies.  
Interestingly, two factors that have been shown to influence the effectiveness of a 
surgery are how the surgery was performed and who performed it. Video-assisted 
thoracoscopic surgery or VATS is a relatively recently developed surgical approach that 
allows surgeons to view the inside of the chest cavity and remove the lung through small 
incisions. Contrary to the traditional open thoracotomy which requires a longer incision 
through one or more major muscles of the chest wall and the spreading of ribs to reach 
the lung, a VATS lobectomy has been associated with shorter hospital stays, fewer 
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complication rates and equivalent survival rates when compared to open lobectomy 
especially when used to resect early stage NSCLC
43-53
. Furthermore, several studies have 
shown lower complication rates and better long-term survival after anatomic pulmonary 
resections performed by thoracic and cardiac surgeons instead of general surgeons
54-57
. 
As the tumor sizes in our study were very large it is likely that many of the patients who 
underwent a lobectomy had it performed via thoracotomy although information regarding 
method of surgical procedure or surgeon subspecialty is unavailable in the SEER 
database and thus was not accounted for in our analysis.  
Tumor size has been recognized as a significant prognostic factor of survival 
outcomes, particularly in patients with early stage NSCLC
15,58,59
. Similarly, Morgensztern 
and colleagues recently demonstrated that tumor size is an independent predictor of 
overall and lung-cancer specific survival in patients with locally advanced disease. 
Patients with stage IIIA tumors >7 cm had a 14% increased risk of death from any cause 
and an 18% increased risk of lung cancer death in comparison to stage IIIA tumors 5.1-7 
cm in diameter. Moreover, the influence of tumor size on survival was reflected in the 
improved OS and LCSS of patients with stage IIIB with small tumors than Stage IIIA 
with larger tumors
60
. In our study, increasing tumor size was also associated with a higher 
risk in both overall and lung-cancer specific mortality upon multivariate analysis of the 
surgical subcohort. Tumors >10 cm in specific had significantly worse outcomes when 
compared to any smaller tumor size category. This finding suggests a potential size cutoff 
at 10 cm from which maximum therapeutic benefit on survival can be expected. The 
decision for surgical resection of tumors >10 cm should be approached with caution as 
we believe that the observed worse outcomes in these patients may be in part the result of 
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a greater incidence of perioperative complications and postoperative residual disease. For 
patients treated with neoadjuvant radiation therapy prior to surgery, tumor size was not a 
significant predictor of OS (P=.18) and LCSS (P=.2).  
This study has several limitations that are generally inherent in any retrospective 
study of large databases. Information regarding the administration of chemotherapy, 
either as neoadjuvant or adjuvant therapy, is unavailable in the SEER database therefore 
we could not comment on the influence of neoadjuvant chemotherapy alone or 
neoadjuvant chemotherapy when used concurrently with radiotherapy therapy on long-
term survival of patients with T3>7 cmN0 NSCLC. It was also not possible to discern if 
some of the patients underwent their neoadjuvant radiation therapy as part of a treatment 
paradigm for a superior sulcus tumor. It is both possible and likely that some superior 
sulcus tumors were included in this study, but presumably this number was reflective of 
the proportion of superior sulcus tumors resected in the overall thoracic surgery 
population which is less than 5%
61,62
.  Arguably, the most significant limitation of this 
study is the lack of knowledge regarding the use of adjuvant chemotherapy. In the study 
period, the authors recognize that data emerged showing a benefit of adjuvant 
chemotherapy for resected tumors >4 cm
19
. In the SEER database there is no ability to 
discern which patients with tumors >7 cm received adjuvant chemotherapy and therefore, 
the primary surgery cohort invariably included this subset of patients. Additionally, no 
information regarding radiotherapy technique including total dose, fraction size, and 
beam energy was available and was therefore not accounted for in our analysis. 
Variations in chemotherapy and radiotherapy regimens are likely in our study population 
and may have influenced the lack of significant NRT benefit on survival over anatomic 
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pulmonary resection alone. However, this study did adjust for all available patient and 
tumor characteristics.  
In conclusion, the administration of neoadjuvant radiation therapy that most likely 
represented chemoradiation therapy prior to surgery was not associated with 
improvements in overall or lung-cancer specific survival as compared to primary surgical 
therapy. Therefore, despite the large tumor size there is no significant associated benefit 
from the use of neoadjuvant therapy for NSCLC tumors >7 cm with no lymph node 
involvement. Respectable survival can be achieved after pulmonary anatomic resection in 
this patient population. In terms of surgical approach, a lobectomy over pneumonectomy 
appears to have a more favorable associated survival irrespective of tumor size, age, 
gender, and histology. Tumors <10 cm in size, particularly tumors 7.1-7.9 cm, are 
associated with the best long-term survival after surgery.  
 
T3>7 cmN1 NSCLC, NCDB Study 
After assessing survival outcomes associated with neoadjuvant therapy followed 
by surgery for very large, node-negative NSCLC tumors, we sought to evaluate the effect 
of neoadjuvant therapy and other various forms of multimodality therapy on long-term 
survival of similarly sized tumors with positive lymph node involvement as studies are 
lacking in this subpopulation of recently upstaged Stage IIIA disease. This study 
demonstrates that patients who underwent multimodality therapy incorporating 
chemotherapy in a neoadjuvant or adjuvant fashion had a significantly reduced likelihood 
of death compared to those who underwent localized therapy or definitive 
chemoradiation therapy.  
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Improved survival of patients with locoregionally advanced NSCLC after 
induction therapy has been demonstrated by several studies and is thought to reflect early 
control of local and distant micrometastasis. In a randomized clinical trial involving 60 
patients with Stage IIIA NSCLC, Rosell and colleagues observed that preoperative 
chemotherapy with mitomycin, ifosfamide, and cisplatin followed by surgery resulted in 
a significantly increased median survival of 26 months compared to 8 months in patients 
treated with surgery alone
63
. In another trial performed at M.D. Anderson Cancer Center, 
60 patients with clinical Stage IIIA NSCLC were randomly assigned between 1987 and 
1993 to receive neoadjuvant chemotherapy with cyclophosphamide, etoposide, and 
cisplatin followed by surgery or surgery alone. This trial demonstrated a median survival 
and 3-year survival rate of 64 months and 60%, respectively, for patients who underwent 
neoadjuvant chemotherapy compared to 11 months and 15%, respectively, for patients in 
the surgery only treatment group
64
. Both of these trials show evidence of improved 
survival rates with neoadjuvant chemotherapy. Several critiques exist for these trials in 
that they were small, involved a heterogeneous set of Stage IIIA lesions, and included 
adjuvant therapy in the form of radiotherapy or more systemic therapy. Furthermore, 
other trials have failed to demonstrate any significant survival benefit with induction 
chemotherapy for locally advanced NSCLC
23
. Neoadjuvant chemoradiation therapy 
studies have also shown that it is both safe and feasible to administer to patients with 
stage III NSCLC although there are mixed results in terms of its exact survival 
benefit
21,23,36,37,65-69
 . Potential disadvantages to this trimodality therapy approach include 
delayed control of the primary tumor with surgery and an increase in surgical morbidity 
and mortality after induction therapy. However, the findings of this study clearly 
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demonstrates an improvement in survival associated with neoadjuvant chemotherapy 
with or without radiation therapy followed by surgery for patients with T3>7cmN1 NSCLC 
lesions in comparison to surgery alone. 
For patients treated with surgery followed by adjuvant chemotherapy in our study 
there was a significantly improved 5-year OS estimate of 38% compared to 16-18% for 
local surgical therapy (surgery alone or S-PORT). While a few trials and meta-analyses 
have demonstrated that adjuvant cisplatin-based chemotherapy can significantly improve 
long-term survival in select groups of Stage II and IIIA NSCLC patients
70
, many other 
trials have failed to show an advantage in disease-free survival or overall survival with 
postoperative chemotherapy
71-74
. Problems such as inconsistent or mixed staging, lack of 
effective chemotherapeutic agents prior to the 1990s, and incomplete administration of 
planned doses have been prevalent issues within these studies. Interestingly, this study 
shows that the timing of chemotherapy administration with respect to surgery does not 
appear to affect survival. Neoadjuvant chemotherapy with or without radiotherapy 
produced similar survival rates compared to adjuvant chemotherapy in the PST cohort 
which were significant compared to surgery only and definitive chemoradiation.  
Among the PST subcohorts that received systemic therapy, adjuvant 
chemoradiation therapy was an exception in that it had an associated survival benefit that 
was not significant (HR 0.5 [0.19-1.34], P=.17) compared to the others. Several 
randomized controlled trials primarily involving patients with positive N2 nodal disease 
such as the North American Intergroup trial E3590 have not shown any improvement in 
disease-free and overall survival when radiation therapy is added to adjuvant 
chemotherapy
66,75,76
. However, no sub-analysis on the effects of treatment on survival of 
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patients with T3>7cmN1 NSCLC lesions if present has been performed. The small sample 
size of patients who underwent adjuvant chemoradiation therapy may have influenced the 
lack of significance for the 40% reduction in likelihood of death associated with S-CxR 
over surgical resection only and warrants for further investigation of this finding on a 
larger scale. Overall, these results suggest that the continuous debate of which form of 
multimodality therapy is superior for managing locally advanced disease is irrelevant 
when pertaining to T3>7cmN1 lesions.   
Various patient and tumor characteristics can render a patient a poor surgical 
candidate. Multiple comorbidities, poor pulmonary function, and significant spread of 
disease are all factors that are known to lead to a worse prognosis, a realization that has 
encouraged the discovery of the most optimal treatment strategy in medically inoperable 
patients with locally advanced disease. Many earlier trials that evaluated the effectiveness 
of sequential or concurrent chemotherapy with radiotherapy in comparison to 
radiotherapy alone for unresectable Stage III NSCLC demonstrated improved though 
non-significant survival times
77-80
. However, the average cohort size was small with 
about 150 patients and there was much variability regarding chemotherapeutic agents 
used and the administration of radiotherapy between these trials. Improvements in 
platinum chemotherapy and radiotherapy techniques later on likely influenced the change 
in observing a significant survival advantage associated with this bimodality 
treatment
81,82
. In the Cancer and Leukemia Group B (GALGB) 8433 trial in particular, 
patients with Stage III NSCLC who were treated with sequential chemotherapy followed 
by radiation therapy were estimated to have a 2.8 fold higher 5-year OS estimate than 
patients who received radiotherapy alone
83
. In our study, definitive chemoradiation 
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therapy was the most prevalent nonsurgical treatment strategy with similarly significant 
improvements in long-term survival in comparison to radiation therapy or chemotherapy 
alone (5-year OS: 11%, 2%, 5%, respectively).     
As discussed in our T3>7cmN0 NSCLC SEER analysis study, tumor size has been 
recognized as a significant prognostic factor of survival outcomes, particularly for early 
stage disease. In this study, tumor size was not found to be an independent predictor of 
overall survival upon multivariate analysis of the entire cohort. However, tumor size 
became a significant factor when analyzing the PST cohort only. Similar to T3>7cmN0 
NSCLC tumors ≥10 cm that were surgically resected, patients in the PST cohort 
exhibited significantly worse outcomes in survival with a hazard ratio of 1.9 (CI, 1.2-3) 
when compared to tumors 7.1-7.9 cm. These results suggest a potential hazard associated 
with surgical resection in the absence or presence of neoadjuvant or adjuvant therapy 
when treating very large tumors. Therefore the decision for surgical resection of tumors 
≥10 cm should be approached with caution as surgery appears to provide a significant 
survival advantage only when part of a multimodality therapy involving systemic 
therapy.  
 Although the NCDB contains a wealth of clinicopathologic and treatment data, 
this study has several limitations in addition to the ones that are generally inherent to any 
retrospective study of large databases. A major limitation was that knowledge of the 
performance status of the patients in each group was not available. Therefore, patients 
with better performance statuses may have been eligible and undergone more 
interventional treatments (such as surgery with chemotherapy) associated with improved 
survival which may have influenced the findings of this study. The majority of the 
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patients in this study did not undergo surgery, and so while this scenario certainly is 
plausible, it would seem unlikely that this explanation was the sole rationale for the 
selection of the treatment modalities. Similarly, excluding the patients with positive 
margins may have resulted in a group of surgery patients who would have been more 
biased toward experiencing more favorable outcomes.  
Information regarding chemotherapy, radiation therapy, or surgical therapy 
administered is variable with many therapy descriptions being grouped into broad 
categories defined by the NCDB. In the NCDB there is no ability to discern which 
patients among those who received neoadjuvant chemotherapy prior to surgery (C-S, 
CxR-S) also received adjuvant systemic therapy and therefore, these groups invariably 
included this subset of patients. Pathologic “surprise” mediastinal lymph node 
involvement (N2), although only comprising 11% of the PST cohort, may have 
influenced the selected use of adjuvant chemotherapy or chemoradiation following 
surgical resection in some of these patients who generally have poorer outcomes due to 
greater lymph node spread of their disease. While this consideration has the potential to 
lower the effects of adjuvant systemic therapy on survival, it reinforces the observed 
significant survival advantage associated with adjuvant chemotherapy following surgical 
resection. Similar to the broad definitions of therapy, information regarding specific 
details of staging such as CT/PET scans and brain MRI imaging or type of lymph node 
staging procedure is unavailable in the NCDB. Additionally, our primary endpoint was 
overall survival as information on lung-cancer specific survival is lacking in the NCDB. 
However, this study did adjust for all available patient and tumor characteristics. Lastly 
and cumulatively, since the NCDB is a cancer registry it is difficult to isolate a possible 
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pathophysiologic mechanism for the observed differences in survival. Indubitably, these 
most likely are multifactorial in origin. 
Lymph node downstaging has been associated with improved survival and has 
been used to gauge the efficacy of chemoradiation therapy
22,84,85
. Determining whether 
downstaging has occurred depends upon the knowledge of lymph node involvement prior 
to the initiation of chemoradiation therapy coupled with pathologic information following 
resection. For patients who received induction chemotherapy or chemoradiation in this 
study, it is not possible to determine which patients were truly downstaged with systemic 
therapy prior to surgical resection. Moreover, there is the possibility that a reduction in 
tumor size and lymph node sterilization after neoadjuvant chemotherapy or 
chemoradiation allowed for a more conservative resection such as a lobectomy over a 
pneumonectomy in this group resulting in a selection bias. A more surprising finding 
from the available pathologic lymph node data available is the fact that there is a 
considerable percentage of patients that had no known pathologic lymph node status (Nx) 
identified. It is unclear if this observation is secondary to either the true 
underperformance of lymph nodes sampling at the time of resection or an artifact of data 
collection. 
 This study is one of the largest known national database studies focused on 
evaluating the effects of widely practiced treatment algorithms on long-term survival of 
patients with T3>7cmN1 NSCLC. Although approximately two-thirds of the patients were 
treated nonsurgically, pulmonary resections with chemotherapy, either with neoadjuvant 
or adjuvant therapy, were associated with the best 5-year overall survival. Systemic 
therapy in a multimodality setting appears to be crucial in maximizing long-term survival 
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regardless of timing of administration to surgical resection. Finally, when surgical 
resection is not feasible, definitive chemoradiation therapy should be considered as an 
equal alternative to surgical resection alone when treating Stage IIIA-N1 NSCLC disease.  
 In general, very large tumors that are greater than 7 cm with no or minimal hilar 
lymph node involvement present a unique set of problems for clinicians. Even though 
complete resection of these tumors may appear daunting, both studies revealed that the 
majority of surgical patients were able to achieve complete resection via a lobectomy 
which is a more conservative surgical approach that was associated with significant 
improvements in long-term survival compared to a pneumonectomy. However, caution 
should be taken when dealing with tumors ≥10 cm in size regardless of lymph node 
involvement. While trimodality therapy in the form of neoadjuvant or adjuvant therapy 
with surgery was associated with the best survival outcomes in patients with very large 
tumors with positive hilar lymph node involvement, the same does not appear to be true 
for cases of node-negative disease. Neoadjuvant therapy followed by surgery for 
treatment of T3>7 cmN0 NSCLC was associated with a modest trend toward improved 
survival when compared to surgery alone although these results were shown to be non-
significant. Taken into context of the overall staging system, T3>7 cmN0 NSCLC tumors 
tend to behave like other subsets of early stage NSCLC lesions in that multimodality 
therapy with surgery following neoadjuvant therapy does not appear to offer a greater 
survival advantage. The spread of disease to local hilar lymph nodes in T3>7 cmN1 
NSCLC makes the optimal treatment strategy less straight-forward. However, it appears 
that several approaches to multimodality therapy are beneficial in this subset of patients 
as long as systemic therapy is involved.   
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TABLE 2- Multivariate analysis on overall and lung cancer-related mortality for overall cohort  
 
 Overall Mortality Lung Cancer-Specific Mortality 
RISK FACTOR HR (95% CI) P Value HR (95% CI) P value 
Sex 
    Male 













Age at diagnosis 
    20-59  yr 
    60-69 yr 
    70-79 yr 





















Tumor size, cm  
    7.1-7.9 
    8-8.9 
    9-9.9 
    10-11.9 

























Type of Surgery 
    Lobectomy 
















TABLE 3- Multivariate analysis on overall and lung cancer-related mortality for NRT sub-cohort 
 
 Overall Mortality Lung Cancer-Specific Mortality 
RISK FACTOR HR (95% CI) P Value HR (95% CI) P value 
Sex 
    Male 














    SCC 
    Adenosquamous 
    Adenocarcinoma 
    Large Cell 

























Age at diagnosis  .11  .91 
Tumor size  .18  .2 
Type of Surgery  .86  .7 
 
 


































T3>7 cmN1 NSCLC, NCDB Study 

















    
 
  Male, n (%) 390 (61) 92 (61) 133 (64) 128 (62) 37 (48) .11 
  Female 252 (39) 58 (39) 76 (36) 78 (38) 40 (52)  
Race  
    
 
  Black 89 (14) 35 (23) 25 (12) 19 (9) 10 (13) .01 
  Other 14 (2)   ***   ***   ***   ***  
  White 539 (84) 112 (75) 178 (85) 183 (89) 66 (86)  
Histology  
    
 
  Adenocarcinoma 139 (22) 39 (26) 41 (20) 46 (22) 13 (17) .26 
  Other 224 (35) 59 (39) 70 (33) 66 (32) 29 (38)  
  Squamous cell 279 (43) 52 (35) 98 (47) 94 (46) 35 (45)  
Tumor Location  
    
 
  LLL 101 (16) 17 (11) 36 (17) 36 (17) 12 (16) .21 
  LUL 183 (29) 46 (31) 58 (28) 58 (28) 21 (27)  
  RLL 110 (17) 16 (11) 37 (18) 44 (21) 13 (17)  
  RML 22 (3)   ***   ***   ***   ***  
  RUL 226 (35) 67 (45) 70 (33) 60 (29) 29 (38)  
Tumor Size  
    
 
  7.1-7.9 cm 136 (21) 37 (25) 38 (18) 47 (23) 14 (18) .78 
  8-8.9 cm 238 (37) 57 (38) 79 (38) 70 (34) 32 (42)  
  9-9.9 cm 121 (19) 25 (17) 45 (22) 39 (19) 12 (15)  















Surgical Approach  
    
 
  Lobectomy 131 (21) 48 (32) 37 (18) 39 (19)  *** <.001 
  Pneumonectomy 86 (13) 24 (16) 39 (19) 21 (10)   ***  
  Nonsurgical 316 (49) 62 (41) 118 (56) 96 (47) 40 (52)  
  None 109 (17) 16 (11) 15 (7) 50 (24) 28 (36)   
Therapy  
    
 
  CxR  184 (29) 39 (26) 80 (38) 54 (26) 11 (14) <.001 
  Chemo  65 (10) 15 (10) 22 (11) 17 (8) 11 (14)  
  RT  67 (10)   *** 16 (8) 25 (12) 18 (23)  
  None 109 (17) 16 (11) 15 (7) 50 (24) 28 (36)  
  CxR-S 31 (5) 15 (10) 11 (5)   ***   ***  
  C-S  25 (4)   *** 11 (5)   ***   ***  
  S 106 (17) 25 (17) 38 (18) 36 (17)   ***  
  S-CxR 10 (2)   ***    ***   ***   ***  
  S-C 34 (5) 14 (9) 12 (6)   ***   ***  
  S-PORT 11 (2)    ***    ***   ***   ***  
Facility  
    
 
  CCP 120 (19) 20 (13) 48 (23) 35 (17) 17 (22) .003 
  Comprehensive  CCP  330 (51) 71 (47) 103 (49) 118 (57) 38 (49)  
  Teaching or research 177 (8) 58 (39) 56 (27) 44 (21) 19 (25)  
  Other 15 (2)    ***    ***   ***    ***  
CCP, community cancer program; C-S, neoadjuvant chemotherapy + surgery; CxR-S, neoadjuvant 
chemoradiation + surgery; CxR, chemoradiation; RT,  radiation therapy; S, surgery; S-C, surgery + 




TABLE 5- Multivariate analysis predicting overall survival among the overall cohort 
Risk Factor HR 95% CI L 95% CI U P value 
Age         
  20-59 yr 1.00 
  
  
  60-69 yr 1.18 0.93 1.5 .17 
  70-79 yr 2.1 1.65 2.67 <.001 
  80+ yr 2.01 1.48 2.74 <.001 
Type of Surgery 
   
  
  Lobectomy 1.00 
  
  
  Pneumonectomy 1.49 1.08 2.05 .01 
Therapy 
   
  
  CxR 1.00 
  
  
  Chemo 1.25 0.93 1.68 .13 
  RT  1.5 1.12 2.01 .007 
  None 2.87 2.23 3.69 <.001 
  CxR- S 0.41 0.19 0.9 .03 
  C-S 0.4 0.18 0.88 .02 
  S 0.8 0.41 1.54 .5 
  S-CxR 0.5 0.19 1.34 .17 
  S-C 0.4 0.19 0.85 .02 
  S-PORT   ***   ***    ***   *** 
HR, Hazard ratio; 95% CI L, lower limit; 95 CI U, upper limit; CCP, community cancer program; C-S, 
neoadjuvant chemotherapy + surgery; CxR-S, neoadjuvant chemoradiation + surgery; CxR, 
chemoradiation; RT,  radiation therapy; S, surgery; S-C, surgery + adjuvant chemotherapy; S-CxR,  surgery 
+ adjuvant chemoradiation; S-PORT,  surgery + postoperative radiation therapy. 




TABLE 6- Multivariate analysis predicting overall survival among the PST cohort 
Risk factor HR  95% CI L 95% CI U P value 
Age         
  20-59 yr 1.00 
  
  
  60-69 yr 1.18 0.79 1.77 .42 
  70-79 yr 2.48 1.63 3.77 <.001 
  80+ yr 2.9 1.33 6.36 .008 
Tumor Size 
   
  
  7.1-7.9 cm 1.00 
  
  
  8-8.9 cm 1.09 0.71 1.67 .68 
  9-9.9 cm 1.36 0.8 2.29 .25 
  ≥10 cm 1.89 1.2 3 .007 
Type of Surgery  
   
  
   Lobectomy 1.00 
  
  
  Pneumonectomy 1.43 1.02 1.99 .04 
Therapy 
   
  
  S 1.00   
  CxR- S 0.5 0.3 0.85 .01 
  C-S 0.54 0.32 0.93 .02 
  S-C   0.49 0.31 0.78 .003 
  S-CxR 0.6 0.26 1.35 .22 
  S-PORT 1.29 0.66 2.53 .46 
HR, Hazard ratio; 95% CI L, lower limit; 95 CI U, upper limit; CCP, community cancer program; C-S, 
neoadjuvant chemotherapy + surgery; CxR-S, neoadjuvant chemoradiation + surgery; CxR, 
chemoradiation; RT,  radiation therapy; S, surgery; S-C, surgery + adjuvant chemotherapy; S-CxR,  surgery 





Fig. 4. Overall survival estimates for overall cohort stratified by primary therapy. PST, primary surgical 
therapy; NST, nonsurgical therapy. 
 
 
Fig. 5. Overall survival estimates for A) NST and B) PST cohorts stratified by therapy. C-S, neoadjuvant 
chemotherapy + surgery; CxR-S, neoadjuvant chemoradiation + surgery; CxR, chemoradiation; RT,  
radiation therapy; S, surgery; S-C, surgery + adjuvant chemotherapy; S-CxR,  surgery + adjuvant 
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